Olutasidenib

From WikiProjectMed
Jump to navigation Jump to search
Olutasidenib
Names
Trade namesRezlidhia
Other namesFT-2102
Clinical data
Drug classIDH1 inhibitor[1]
Main usesAcute myeloid leukemia[1]
Side effectsNausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, diarrhea[1]
Routes of
use		By mouth
Typical dose150 mg BID[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Chemical and physical data
FormulaC18H15ClN4O2
Molar mass354.79 g·mol−1
3D model (JSmol)
  • C[C@H](NC1=CC=C(C#N)N(C)C1=O)C1=CC2=C(NC1=O)C=CC(Cl)=C2
  • InChI=InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1
  • Key:NEQYWYXGTJDAKR-JTQLQIEISA-N

Olutasidenib, sold under the brand name Rezlidhia, is an medication used to treat acute myeloid leukemia.[1] Specifically it is used in those with certain IDH1 mutations who have failed other treatments.[1] It is taken by mouth.[1]

Common side effects include nausea, tiredness, joint pain, constipation, shortness of breath, fever, rash, inflammation of the mouth, and diarrhea.[1] Common lab abnormalities include high potassium, low sodium, liver problems, and kidney problems.[1] Other side effects may include differentiation syndrome.[1] It is an isocitrate dehydrogenase-1 (IDH1) inhibitor.[1]

Olutasidenib was approved for medical use in the United States in 2022.[1] In the United States it costs about 32,200 USD per month as of 2022.[4]

Medical uses

Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.[2][3][5]

Dosage

It is taken at a dose of 150 mg twice per day.[1]

Society and culture

Names

Olutasidenib is the international nonproprietary name.[6]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 "REZLIDHIA™ (olutasidenib) capsules, for oral use". Archived from the original on 15 January 2023. Retrieved 15 January 2023.
  2. ↑ 2.0 2.1 "Archive copy" (PDF). Archived (PDF) from the original on 2022-12-13. Retrieved 2022-12-20.{{cite web}}: CS1 maint: archived copy as title (link)
  3. ↑ 3.0 3.1 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215814Orig1s000ltr.pdf Archived 2022-12-20 at the Wayback Machine Public Domain This article incorporates text from this source, which is in the public domain.
  4. ↑ "Optum Rx Revenue Grows 9% in 2022". Formulary Watch. Archived from the original on 15 January 2023. Retrieved 15 January 2023.
  5. ↑ "FDA approves olutasidenib". U.S. Food and Drug Administration (FDA). 1 December 2022. Archived from the original on 20 December 2022. Retrieved 20 December 2022.
  6. ↑ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

External links

External sites:
Identifiers:
Retrieved from "https://mdwiki.org/w/index.php?title=Olutasidenib&oldid=1404504"